ClinicalTrials.gov record
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

ClinicalTrials.gov ID: NCT04919642

Public ClinicalTrials.gov record NCT04919642. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced Cholangiocarcinoma

Study identification

NCT ID
NCT04919642
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Industry
Enrollment
55 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 6, 2021
Primary completion
Feb 27, 2024
Completion
Feb 27, 2024
Last update posted
Jun 24, 2024

2021 – 2024

United States locations

U.S. sites
32
U.S. states
18
U.S. cities
28
Facility City State ZIP Site status
Providence Cancer Center Anchorage Alaska 99508
City of Hope Duarte California 91010
University of California, Los Angeles, School of Medicine Santa Monica California 90404
USO Oncology Network- Rocky Mountain Cancer Centers Denver Colorado 80218-1237
Mount Sinai Medical Center Miami Beach Florida 33140
University of Chicago Medical Center - Duchossis Center for Advanced Medicine Chicago Illinois 60637-1426
University of Maryland - Marlene and Stewart Greenebaum Cancer Center Baltimore Maryland 21250
University of Michigan Comprehensive Cancer Center Ann Arbor Michigan 48109
Henry Ford Health Center Detroit Michigan 48202
Mayo Clinic Rochester Minnesota 55905
Comprehensive Cancer Center of Nevada Las Vegas Nevada 89169
Summit Medical Group - Florham Park Campus Florham Park New Jersey 07932
Roswell Park Comprehensive Cancer Center Buffalo New York 14203
Ruttenberg Treatment Center - Mount Sinai New York New York 10029
USOR Oncology Network- New York Oncology New York New York 12208
Stony Brook University - Long Island Cancer Center Stony Brook New York 11794
University of Cincinnati Cancer Institute Cincinnati Ohio 45219
University Hospitals Seidman Cancer Center Cleveland Ohio 44106
USO Oncology Network-Northwest Cancer Specialists, P.C. Portland Oregon 97227
Medical College of South Carolina Charleston South Carolina 29425
The University of Tennessee Medical Center Knoxville Tennessee 37920
Sarah Cannon Research Institute at Tennessee Oncology Nashville Tennessee 37203
Methodist Dallas Medical Center Dallas Texas 75203
Parkland Health & Hospital System Dallas Texas 75235
University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center Dallas Texas 75235
Houston Methodist Hospital - Outpatient Center Houston Texas 77030
UT MD Anderson Cancer Center Houston Texas 77030
USO Oncology Network-Texas Oncology Tyler Texas 75702-8363
USO Oncology Network-Virginia Oncology Associates - Brock Cancer Center - Norfolk Norfolk Virginia 23502-2824
USO Oncology Network-Oncology and Hematology Associates of Southwest Virginia, Inc. Roanoke Virginia 24014
University of Wisconsin School of Medicine and Public Health Madison Wisconsin 53705
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04919642, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 24, 2024 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04919642 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →